Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells

Blood Research
Ha-Yon KimDeog-Yeon Jo

Abstract

The C-X-C chemokine receptor 7 (CXCR7) has been shown to be a decoy receptor for CXCR4 in certain cell types. We investigated the expression status and functional roles of CXCR7 in acute myeloid leukemia (AML) cells in vitro. CXCR7 mRNA was knocked down in AML cells by using small interfering RNA (siRNA) technology, and subsequent biological alterations in the cells were evaluated in vitro. All AML cell lines examined in this study (U937, K562, KG1a, HL-60, and MO7e) and primary CD34(+) cells obtained from patients with AML expressed CXCR7 mRNA at various levels. Western blotting showed that all AML cells produced CXCR7. Furthermore, all AML cells expressed CXCR7 in both the cytoplasm and on the cell surface at various levels. Stromal cell-derived factor-1 (SDF-1; C-X-C motif ligand 12 (CXCL12)) induced internalization of cell surface CXCR7. However, neither hypoxia nor the examined hematopoietic growth factors (interleukin-1β (IL-1β), IL-3, IL-6, granulocyte-colony-stimulating factor, granulocyte, macrophage-colony-stimulating factor, and stem cell factor) and proinflammatory cytokines (interferon-γ, transforming growth factor-β, and tumor necrosis factor-α) were found to alter cell surface CXCR7 expression. The transfection o...Continue Reading

References

Apr 18, 2002·Leukemia·C VoermansC E van Der Schoot
Nov 5, 2003·The Journal of Experimental Medicine·Tiziana SchioppaAntonio Sica
Aug 19, 2005·The Journal of Biological Chemistry·Karl BalabanianFrançoise Bachelerie
Jul 5, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Florence DommangeUNKNOWN GOELAMS Study Group
Sep 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Frederic SierroFabienne Mackay
Sep 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Zhenhua MiaoThomas J Schall
Dec 7, 2007·The Journal of Biological Chemistry·Jianhua WangRussell S Taichman
Feb 13, 2008·The Journal of Experimental Medicine·Benedetta MazzinghiPaola Romagnani
Jun 3, 2008·Journal of Neuroimmunology·Bastian SchönemeierRalf Stumm
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Sudarshan RajagopalRobert J Lefkowitz
Feb 18, 2010·PloS One·Ulrike NaumannMarcus Thelen
Jun 29, 2010·Current Cancer Drug Targets·C D'AlterioS Scala
Sep 28, 2010·Biochemical and Biophysical Research Communications·Hongbao LiuXiaohui Tian
Oct 5, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Robert D BerahovichThomas J Schall
Jan 12, 2011·Neuron·Yanling WangJohn L R Rubenstein
May 9, 2013·Molecular Biology Reports·Aparecida de Lourdes PerimMaria Angelica Ehara Watanabe
Nov 28, 2013·Blood·Frédéric TorossianMarie-Caroline Le Bousse-Kerdilès
Mar 19, 2014·Molecular Cancer·Benoît RomainDominique Guenot

❮ Previous
Next ❯

Citations

Sep 7, 2016·Expert Opinion on Drug Discovery·Federica BarbieriTullio Florio
Feb 13, 2018·Stem Cell Research & Therapy·Rita de Cassia Carvalho MeloSara Teresinha Olalla Saad
May 28, 2020·International Journal of Molecular Sciences·Magdalena GroblewskaBarbara Mroczko
Aug 6, 2020·Frontiers in Cell and Developmental Biology·Alicia VillatoroLorena Arranz
Jan 21, 2021·International Journal of Molecular Sciences·Jan KorbeckiIrena Baranowska-Bosiacka

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR
electrophoresis
transfection
fluorescence microscopy

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.